Bio-Path (NASDAQ:BPTH) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH) in a research report released on Wednesday. The brokerage issued a sell rating on the stock.

Separately, Roth Mkm reiterated a “buy” rating and issued a $20.00 price objective on shares of Bio-Path in a research report on Monday, July 8th.

Bio-Path Trading Up 2.8 %

NASDAQ:BPTH opened at $1.10 on Wednesday. The firm’s fifty day moving average price is $1.05 and its 200 day moving average price is $1.82. Bio-Path has a 1-year low of $0.85 and a 1-year high of $14.42.

Bio-Path (NASDAQ:BPTH) last issued its quarterly earnings results on Thursday, August 15th. The company reported ($1.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.54) by $0.38. During the same quarter last year, the business earned ($10.60) EPS. Research analysts expect that Bio-Path will post -6.2 EPS for the current year.

Institutional Investors Weigh In On Bio-Path

An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC bought a new stake in Bio-Path Holdings, Inc. (NASDAQ:BPTH) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned approximately 4.66% of Bio-Path as of its most recent filing with the Securities and Exchange Commission. 5.74% of the stock is owned by institutional investors.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.